<DOC>
	<DOCNO>NCT01134315</DOCNO>
	<brief_summary>The objective study observe safety paricalcitol utilization pediatric participant ( age 0 16 year old ) treat secondary hyperparathyroidism ( SHPT ) . Participants follow minimum 3 month approximately 36 month monitor incidence hypercalcemia ( high calcium level blood ) .</brief_summary>
	<brief_title>Study Evaluate Safety Vitamin D Receptor Activators Patients Ages 0 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice</brief_title>
	<detailed_description>Investigators free determine appropriate therapy participant base clinical judgment . Decisions prescribe paricalcitol calcitriol make independently prior enrollment participant observational study .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Hypercalcemia</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>1 . Male female 0 16 year age ( inclusive ) , peritoneal dialysis least 30 day . 2 . The patient history secondary hyperparathyroidism define initiated vitamin D receptor activator treat elevate parathyroid hormone level . 3 . The patient attend site associate North America Pediatric Renal Trials Collaborative Studies ( NAPRTCS ) Dialysis Registry . 4 . Patient patient 's parent legal guardian must voluntarily sign date inform consent and/or assent , approve local Independent Ethics Committee/Institutional Review Board , prior initiation screen studyspecific procedure . 5 . Patient receive paricalcitol calcitriol minimum 10 day . 1 . Patient schedule kidney transplant within 3 month . 2 . Patient expect stop peritoneal dialysis within 3 month . 3 . Patient expect transfer hemodialysis within 3 month . 4 . Patient planning enrol investigational study drug and/or dose unknown investigator within first 3 month date patient enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Evaluating incidence hypercalcemia pediatric patient</keyword>
</DOC>